Vertex Pharmaceuticals Incorporated $VRTX Stock: MGO One Seven LLC Cuts Holdings

MGO One Seven LLC decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 31.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,469 shares of the pharmaceutical company’s stock after selling 1,112 shares during the period. MGO One Seven LLC’s holdings in Vertex Pharmaceuticals were worth $1,291,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the business. BlackRock Inc. bought a new position in shares of Vertex Pharmaceuticals in the second quarter valued at $11,975,849,000. Bank of America Corp DE bought a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter worth $1,509,651,000. Legal & General Group Plc acquired a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth $928,893,000. Bank of New York Mellon Corp acquired a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth $830,842,000. Finally, Deutsche Bank AG acquired a new stake in shares of Vertex Pharmaceuticals during the second quarter worth $784,391,000. Institutional investors own 90.96% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Daiwa Securities Group raised their target price on Vertex Pharmaceuticals from $555.00 to $556.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Rothschild & Co Redburn upped their price target on Vertex Pharmaceuticals from $570.00 to $580.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Wells Fargo & Company upped their price target on Vertex Pharmaceuticals from $550.00 to $650.00 and gave the company an “overweight” rating in a research report on Tuesday. Jefferies Financial Group increased their price objective on Vertex Pharmaceuticals from $633.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, September 23rd. Finally, Morgan Stanley decreased their price objective on Vertex Pharmaceuticals from $665.00 to $660.00 and set an “overweight” rating for the company in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $596.44.

Vertex Pharmaceuticals Stock Down 1.2%

Shares of VRTX stock opened at $542.50 on Friday. The stock’s 50 day simple moving average is $522.81 and its 200 day simple moving average is $481.42. Vertex Pharmaceuticals Incorporated has a twelve month low of $406.67 and a twelve month high of $568.67. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.74 and a current ratio of 2.34. The company has a market capitalization of $137.69 billion, a price-to-earnings ratio of 34.91, a PEG ratio of 2.84 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). The firm had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.42 billion. Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The business’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $4.80 earnings per share. As a group, research analysts predict that Vertex Pharmaceuticals Incorporated will post 16.50 EPS for the current year.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported third-quarter revenue of $3.44 billion, up about 12% year over year, and raised its 2026 revenue forecast to $13.15 billion–$13.25 billion. Growth was supported by its cystic fibrosis business and newer products, including CASGEVY. The company also faces a key November 30 FDA decision date for povetacicept in IgA nephropathy. Q3 earnings call highlights
• Positive Sentiment: Multiple analysts raised Vertex price targets or reiterated Buy/Overweight ratings, including Barclays, TD Cowen, JPMorgan, Goldman Sachs, Stifel, Cantor Fitzgerald, RBC, UBS, Wells Fargo, and Scotiabank. The broad positive analyst tone points to confidence in the company’s outlook. Barclays price-target increase
• Positive Sentiment: A longer-term bullish view cited Vertex’s strong position in cystic fibrosis and its gradual expansion into other treatments as reasons it could remain an attractive biotech stock. Long-term outlook
• Neutral Sentiment: Third-quarter revenue exceeded analyst estimates, but earnings per share of $4.76 came in slightly below the $4.82 consensus—an offset to the encouraging sales and guidance update.
• Negative Sentiment: Morgan Stanley lowered its expectations for Vertex’s stock price, offering a counterpoint to the wave of target increases. Morgan Stanley outlook

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.